NHD Global
Metabolic & Weight Loss · Dual glucagon/GLP-1 research
Scientific Product Dossier
Survodutide is an investigational peptide agonist designed to activate glucagon and GLP-1 receptors. In the 2026 SYNCHRONIZE-1 phase 3 trial, 725 adults with obesity without diabetes had greater mean body-weight reductions with survodutide than placebo at week 76, while gastrointestinal adverse events were common. Trial results belong to the studied intervention and do not validate this catalog research material.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Mean weight change was −12.2% and −13.0% in the two survodutide groups versus −5.4% with placebo; the study randomized 725 participants.
Adults with obesity without diabetes; investigational trial formulation, not catalog-lot evidence.
Read the primary studyGastrointestinal adverse events occurred in 80.9% and 89.7% of active groups versus 47.9% with placebo.
Protocol-specific human safety data; no deaths were reported in the paper.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
le Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
View primary recordClinicalTrials.gov NCT06066515.
View primary recordThird-party publications selected for direct relevance.
le Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
ClinicalTrials.gov NCT06066515.
Concise answers for researchers comparing identity, evidence and catalog variants.
Survodutide is designed as a dual glucagon-receptor and GLP-1-receptor agonist.
In 725 adults with obesity without diabetes, both studied survodutide groups produced statistically greater mean weight reductions than placebo at week 76. Gastrointestinal adverse events were common.
No equivalence is asserted. Trial identity, formulation and manufacturing controls are separate from this research-use catalog lot.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response and adverse-event pattern—not…
Updated August 28, 2026
Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. “Dual agonist” describes receptor pharmacology; it is not a certificate of clinical status…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: SUR10 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
